Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
1. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone.
2. The method of claim 1 , wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule and the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base.
3. The method of claim 1 , wherein the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
4. The method of claim 1 , wherein the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
5. The method of claim 1 , wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule, the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base, and the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
6. The method of claim 1 , wherein the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule, the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base, and the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
7. The method of claim 1 , wherein the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.
8. The method of claim 1 , wherein the method consists of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone.
9. The method of claim 1 , wherein the fosnetupitant independently prevents acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
10. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein:
(a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule;
(b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; and
(c) the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
11. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, comprising intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein:
(a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule;
(b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base; and
(c) the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule.
12. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, consisting of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein:
(a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule;
(b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base;
(c) the solution has a concentration of from 2 mg/mL to 5 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule; and
(d) the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.
13. A method for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy, consisting of intravenously administering to the human patient, prior to the chemotherapy, a solution comprising a therapeutically effective amount of the chloride hydrochloride salt of fosnetupitant and a therapeutically effective amount of palonosetron hydrochloride, in combination with a therapeutically effective amount of dexamethasone, wherein:
(a) the chloride hydrochloride salt of fosnetupitant is administered in an amount of from 150 mg to 200 mg based on the netupitant portion of the molecule;
(b) the palonosetron hydrochloride is administered in an amount of 0.25 mg based on the weight of the free base;
(c) the solution has a concentration of from 5 mg/mL to 15 mg/mL of the chloride hydrochloride salt of fosnetupitant based on the weight of the netupitant portion of the molecule; and
(d) the therapeutically effective amount of dexamethasone comprises 12 mg administered orally on day 1, 8 mg administered orally on day 2, 8 mg administered orally on day 3 and 8 mg administered orally on day 4.